| Literature DB >> 28041678 |
Elena E Perez1, Jordan S Orange2, Francisco Bonilla3, Javier Chinen2, Ivan K Chinn2, Morna Dorsey4, Yehia El-Gamal5, Terry O Harville6, Elham Hossny5, Bruce Mazer7, Robert Nelson8, Elizabeth Secord9, Stanley C Jordan10, E Richard Stiehm11, Ashley A Vo12, Mark Ballow13.
Abstract
Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.Entities:
Keywords: IGIV; IVIG; Immune globulin; SCIG; adverse events; autoimmunity; immune modulating; immunoglobulin; immunomodulation; primary immunodeficiency; transfusion
Mesh：
Substances：
Year: 2016 PMID： 28041678 DOI： 10.1016/j.jaci.2016.09.023
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793